Charis E. Teh

2.5k total citations · 1 hit paper
34 papers, 946 citations indexed

About

Charis E. Teh is a scholar working on Immunology, Molecular Biology and Genetics. According to data from OpenAlex, Charis E. Teh has authored 34 papers receiving a total of 946 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Immunology, 11 papers in Molecular Biology and 9 papers in Genetics. Recurrent topics in Charis E. Teh's work include Immune Cell Function and Interaction (14 papers), T-cell and B-cell Immunology (12 papers) and Chronic Lymphocytic Leukemia Research (9 papers). Charis E. Teh is often cited by papers focused on Immune Cell Function and Interaction (14 papers), T-cell and B-cell Immunology (12 papers) and Chronic Lymphocytic Leukemia Research (9 papers). Charis E. Teh collaborates with scholars based in Australia, United States and Singapore. Charis E. Teh's co-authors include Daniel H.D. Gray, Christopher C. Goodnow, Stephen R. Daley, Andreas Strasser, Andrew W. Roberts, Anselm Enders, David C.S. Huang, Rachel Thijssen, Jianan Gong and Mary Ann Anderson and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Blood and Nature Immunology.

In The Last Decade

Charis E. Teh

32 papers receiving 940 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

2018 276 citations Piers Blombery, Mary Ann Anderson et al. Cancer Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Charis E. Teh Australia	16	428	404	234	190	164	34	946
Nadja Zaborsky Austria	18	283 0.7×	386 1.0×	256 1.1×	336 1.8×	138 0.8×	49	945
Bruce R. Rowley United States	5	331 0.8×	575 1.4×	184 0.8×	166 0.9×	102 0.6×	7	950
Justyna Rawluk Germany	9	243 0.6×	260 0.6×	243 1.0×	254 1.3×	126 0.8×	28	666
Šárka Pavlová Czechia	15	443 1.0×	176 0.4×	342 1.5×	258 1.4×	190 1.2×	42	854
Andrea Visentin Italy	20	242 0.6×	322 0.8×	535 2.3×	206 1.1×	270 1.6×	100	994
Ahmed Amine Khamlichi France	22	1.0k 2.4×	714 1.8×	170 0.7×	166 0.9×	111 0.7×	48	1.6k
Leila R. Martins Portugal	14	652 1.5×	255 0.6×	193 0.8×	312 1.6×	79 0.5×	21	1.1k
Michael A. Damore United States	16	302 0.7×	284 0.7×	68 0.3×	276 1.5×	85 0.5×	30	775
Michela Frenquelli Italy	13	367 0.9×	260 0.6×	300 1.3×	88 0.5×	173 1.1×	19	720
Susanne Hipp Germany	15	717 1.7×	298 0.7×	378 1.6×	459 2.4×	220 1.3×	22	1.2k

Countries citing papers authored by Charis E. Teh

Since Specialization

Citations

This map shows the geographic impact of Charis E. Teh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charis E. Teh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charis E. Teh more than expected).

Fields of papers citing papers by Charis E. Teh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charis E. Teh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charis E. Teh. The network helps show where Charis E. Teh may publish in the future.

Co-authorship network of co-authors of Charis E. Teh

This figure shows the co-authorship network connecting the top 25 collaborators of Charis E. Teh. A scholar is included among the top collaborators of Charis E. Teh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charis E. Teh. Charis E. Teh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tiong, Ing Soo, Tamia Nguyen, Chong Chyn Chua, et al.. (2025). Emergent BAX-mutated clonal hematopoiesis after venetoclax-based therapy for breast cancer. Blood Advances. 9(17). 4391–4395.

Tan, Tania, Daniel H.D. Gray, & Charis E. Teh. (2022). Single-Cell Profiling of the Intrinsic Apoptotic Pathway by Mass Cytometry (CyTOF). Methods in molecular biology. 2543. 83–97. 2 indexed citations

Teh, Charis E., Alissa K. Robbins, Darren C. Henstridge, et al.. (2020). MCL-1 is essential for survival but dispensable for metabolic fitness of FOXP3+ regulatory T cells. Cell Death and Differentiation. 27(12). 3374–3385. 2 indexed citations

Teh, Charis E., Jianan Gong, David Segal, et al.. (2020). Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells. Cell Death and Differentiation. 27(7). 2217–2233. 25 indexed citations

Fedele, Pasquale L., Yang Liao, Jianan Gong, et al.. (2020). The transcription factor IRF4 represses proapoptotic BMF and BIM to licence multiple myeloma survival. Leukemia. 35(7). 2114–2118. 21 indexed citations

Chan, Anna, et al.. (2019). Deletion of self-reactive CCR7– thymocytes in the absence of MHC expression on thymic epithelial cells. Cell Death and Differentiation. 26(12). 2727–2739. 5 indexed citations

Gangoda, Lahiru, Charis E. Teh, Michael A. Dengler, et al.. (2019). Characterization of a novel human BFL-1-specific monoclonal antibody. Cell Death and Differentiation. 27(2). 826–828. 3 indexed citations

Dengler, Michael A., Charis E. Teh, Rachel Thijssen, et al.. (2019). Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma. Oncogene. 39(9). 2009–2023. 18 indexed citations

Lindeman, Geoffrey J., Sarah‐Jane Dawson, Jayesh Desai, et al.. (2019). Abstract PD1-06: A phase 1b dose-escalation and expansion study of the BCL-2 inhibitor venetoclax combined with tamoxifen in ER and BCL-2–positive metastatic breast cancer (MBC). Cancer Research. 79(4_Supplement). PD1–6. 3 indexed citations

10.

Blombery, Piers, Mary Ann Anderson, Jianan Gong, et al.. (2018). Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. Cancer Discovery. 9(3). 342–353. 276 indexed citations breakdown →

11.

Salmon, Jessica M., Giovanna Pomilio, Donia M. Moujalled, et al.. (2018). Combined BCL-2 and HDAC Targeting Has Potent and TP53 Independent Activity In AML. Experimental Hematology. 64. S99–S100. 2 indexed citations

12.

Cretney, Erika, Dane M. Newman, Lucille C. Rankin, et al.. (2018). Characterization of Blimp-1 function in effector regulatory T cells. Journal of Autoimmunity. 91. 73–82. 44 indexed citations

13.

Brinkmann, Kerstin, Stephanie Grabow, Craig D. Hyland, et al.. (2017). The combination of reduced MCL-1 and standard chemotherapeutics is tolerable in mice. Cell Death and Differentiation. 24(12). 2032–2043. 18 indexed citations

14.

Schenk, Robyn L., Selma Tuzlak, Emma M. Carrington, et al.. (2017). Characterisation of mice lacking all functional isoforms of the pro-survival BCL-2 family member A1 reveals minor defects in the haematopoietic compartment. Cell Death and Differentiation. 24(3). 534–545. 51 indexed citations

15.

Daley, Stephen R., et al.. (2017). Cell death and thymic tolerance. Immunological Reviews. 277(1). 9–20. 42 indexed citations

16.

Teh, Charis E., Keisuke Horikawa, Carrie Arnold, et al.. (2013). Heterozygous mis-sense mutations in Prkcb as a critical determinant of anti-polysaccharide antibody formation. Genes and Immunity. 14(4). 223–233. 3 indexed citations

17.

Silva, Diego G., Stephen R. Daley, Jennifer J. Hogan, et al.. (2011). Anti-Islet Autoantibodies Trigger Autoimmune Diabetes in the Presence of an Increased Frequency of Islet-Reactive CD4 T Cells. Diabetes. 60(8). 2102–2111. 55 indexed citations

18.

Yabas, Mehmet, Charis E. Teh, Sandra Frankenreiter, et al.. (2011). ATP11C is critical for the internalization of phosphatidylserine and differentiation of B lymphocytes. Nature Immunology. 12(5). 441–449. 102 indexed citations

19.

Teh, Charis E., Stephen R. Daley, Anselm Enders, & Christopher C. Goodnow. (2010). T-cell regulation by casitas B-lineage lymphoma ( Cblb ) is a critical failsafe against autoimmune disease due to autoimmune regulator ( Aire ) deficiency. Proceedings of the National Academy of Sciences. 107(33). 14709–14714. 38 indexed citations

20.

Lee, Sangmi, et al.. (2009). The transcription repressor, ZEB1, cooperates with CtBP2 and HDAC1 to suppress IL-2 gene activation in T cells. International Immunology. 21(3). 227–235. 85 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact